The annual academic premier event in the field of global antiviral therapy—the 26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025—will be held grandly in Amsterdam, the Netherlands, on September 3-4, 2025.

As a top-tier platform focused on optimizing antiviral therapy, the conference convenes leading global experts to deeply explore the latest advancements in antiviral treatment, including topics such as drug-drug interactions, pharmacokinetics, medication in special people living with HIV (PWH), safety, and regulatory affairs, thereby fostering the deep integration of new drug development and clinical application.

The Phase I/II study of Aidea Pharma's novel integrase inhibitor—ACC017 Tablets—has been successfully selected for an oral presentation at this conference, fully demonstrating the company's continuous breakthroughs and academic influence in the field of anti-HIV novel drug research and development.

Dr. Hong Qin, Chief Medical Officer of Aidea Pharma, delivered a presentation at the "Latest R&D Pipeline Progress" session on September 4 at 15:50 local time in the Netherlands, sharing the platform with multinational pharmaceutical giants. The presentation is titled "Antiviral Activity, Safety, and PK/PD of ACCo17 in Antiretroviral Naïve HIV-Infected Adults: A Randomized, Double-Blind, Placebo/Dose-Parallel-Controlled Short-Term Monotherapy Study."

This report unveiled for the first time the groundbreaking research findings of ACC017, an innovative integrase strand transfer inhibitors (INSTI) independently developed by Aidea Pharma: in treatment-naïve PWH, ACC017 tablets achieved a viral load reduction of 1.44-2.34 log10 copies/mL after just 10 days of monotherapy, and when combined with a nucleoside drug, the viral load suppression rate exceeded 90% after 18 days of treatment.

Furthermore, ACC017 exhibited favorable tolerability and safety profiles, with a clear pharmacokinetic/pharmacodynamic (PK/PD) relationship, providing substantial support for its further clinical development as a first-line initial treatment regimen.

Concurrently, three additional poster presentations from Aidea Pharma were exhibited, covering studies on the single-dose pharmacokinetics and safety of ACC017, as well as a food-effect assessment.

Moreover, research on the already-marketed novel non-nucleoside reverse transcriptase inhibitor (NNRTI)—Ainuovirine Tablets (ANV)—was presented, focusing on the impact of pre-existing drug resistance on virological efficacy.

The collective presentation of these four research achievements signifies another significant stride forward for Aidea Pharma in the journey of innovative anti-HIV drug development.

In the future, Aidea Pharma will continue to uphold its innovation-driven development philosophy, leverage scientific capabilities to advance the international antiviral drug R&D process, and contribute to the global shared vision of ending AIDS.